Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin?
作者信息
Katsiki Niki, Triposkiadis Filippos
机构信息
Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece.
Department of Cardiology, Larissa University Hospital, Larissa, Greece.
出版信息
Curr Vasc Pharmacol. 2019;17(4):421-424. doi: 10.2174/1570161116666180831124717.
Abstract
摘要
相似文献
1
Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin?心力衰竭中利尿剂抵抗：恩格列净有作用吗？
Curr Vasc Pharmacol. 2019;17(4):421-424. doi: 10.2174/1570161116666180831124717.
2
Reduced hospitalization for heart failure using anti-diabetic drug dapagliflozin: implications of DECLARE-TIMI 58 for the basic science community.使用抗糖尿病药物达格列净减少心力衰竭住院率：DECLARE-TIMI 58研究对基础科学界的启示
Cardiovasc Res. 2019 May 1;115(6):e54-e57. doi: 10.1093/cvr/cvz073.
3
Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.恩格列净与急性心力衰竭后再住院及死亡风险降低相关。
Circulation. 2019 Mar 12;139(11):1458-1460. doi: 10.1161/CIRCULATIONAHA.118.038339.
4
Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study.恩格列净作为附加疗法对因急性失代偿性心力衰竭住院的糖尿病患者的充血和肾功能的影响：一项前瞻性随机对照研究。
Circ Heart Fail. 2021 Mar;14(3):e007048. doi: 10.1161/CIRCHEARTFAILURE.120.007048. Epub 2021 Mar 5.
5
Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics.恩格列净对心肺适应性的影响及袢利尿剂的显著相互作用。
Diabetes Obes Metab. 2018 Aug;20(8):2014-2018. doi: 10.1111/dom.13309. Epub 2018 Apr 23.
6
Dapagliflozin (Farxiga) - a new indication for heart failure.达格列净（安达唐）——心力衰竭的新适应症。
Med Lett Drugs Ther. 2020 Jun 29;62(1601):102-103.
7
Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.恩格列净在常规临床治疗中心衰住院风险的研究
Circulation. 2019 Jun 18;139(25):2822-2830. doi: 10.1161/CIRCULATIONAHA.118.039177. Epub 2019 Apr 8.
8
Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial.恩格列净起始治疗 2 型糖尿病合并心血管疾病患者后估计液体量减少：安慰剂对照、随机 EMBLEM 试验的二次分析。
Cardiovasc Diabetol. 2021 Jun 28;20(1):105. doi: 10.1186/s12933-021-01295-6.
9
Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.达格列净对合并慢性心力衰竭的 2 型糖尿病患者左心室纵向功能的积极影响。
Cardiovasc Diabetol. 2020 Jan 7;19(1):6. doi: 10.1186/s12933-019-0985-z.
10
Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.恩格列净治疗2型糖尿病合并外周动脉疾病患者的心血管结局及安全性：EMPA-REG OUTCOME研究的亚组分析
Circulation. 2018 Jan 23;137(4):405-407. doi: 10.1161/CIRCULATIONAHA.117.032031. Epub 2017 Nov 13.
Zotero 插件